New Car Smell Threatens Health

A recent Study by Australia's Commonwealth Scientific and Industrial Research Organization (CSIRO) found that the new car smell is an unhealthy "toxic cocktail," that could lead to long term health problems.

Dr. Steve Brown, head of CSIRO's Air Quality Control research says in a CSIRO press release:

"Just as air inside our homes and workplaces is often much more polluted than the air outside, so sitting in a new car can expose you to levels of toxic emissions many times beyond goals established by Australia's National Health & Medical Research Council (NHMRC)".

The new car smell, highly sought after by some, and dreaded by the chemically sensitive, can be attributed to VOC's (volatile organic compounds.)  

A press release from CSIRO listed the following air toxics found in "high levels" in new cars:

  • Benzene - a known human carcinogen linked to bone marrow failure diseases such as: aplastic anemia, myelodysplastic syndromes, and acute myelogenous leukemia,  
  • Acetone - a mucosal irritant
  • Cyclohexanone - a possible human carcinogen
  • Ethylbenzene - a systemic toxic agent
  • MIBK - a systemic toxic agent
  • n-Hexane - a neurotoxic agent
  • Styrene - a probable human carcinogen
  • Toluene - a central nervous system dysfunction agent
  • Xylene isomers - a fetal development toxic agent 

Brown continues:

"To avoid some exposure to this toxic cocktail, people who buy new cars should make sure there is plenty of outside air entering the vehicle while they drive, for at least six months after the vehicle has been purchased, although this may not be possible in heavy traffic due to air toxics from car exhausts. Ultimately, what we need are cars with interior materials that produce low emissions".

This study points out that new car interior VOC levels are significantly reduced after the first six months, and that some manufacturers are already taking measures to reduce toxic materials used in car interiors.

 

 

 

 

Support the Bone Marrow Failure Disease Research and Treatment Act of 2009

While a link between bone marrow failure diseases and benzene exposure has been well established, there is a great need for more research into causes and treatments for these potentially fatal disorders. 

Bone marrow failure diseases, like aplastic anemia, myelodysplastic syndromes, and acute myeloid leukemia (AML), sicken between 20,000 and 30,000 Americans each year.

On February 26, 2009 Representative Dorris O Matusi (D-CA) introduced the Bone Marrow Failure Disease Research and Treatment Act of 2009. The legislation would pool the resources of several federal agencies in order to increase understanding and treatments for the disorders.

The following summary of the bill is courtesy of the Aplastic Anemia & MDS (myelodysplastic syndromes) International Foundation, Inc. (AA&MDSIF).

The legislation directs the Health and Human Services Department to develop a comprehensive 
strategy to combat these diseases, which include: 

• A national bone marrow failure disease registry so that researchers can combine their 
data in one place, yielding more effective research designs and better results; 

• Pilot studies through the Agency for Toxic Substances and Disease Registry to 
determine which environmental factors cause people to acquire bone marrow failure 
diseases; 

• Minority-focused programs to make information on treatment options and clinical trials 
available to minority communities, particularly Hispanic and Asian American 
communities; 

• Agency for Healthcare Research and Quality grants to help improve diagnostic 
practices and quality of care for patients with bone marrow failure diseases. 

In total, the legislation authorizes $8 million annually for fiscal years 2010 through 2014. 

For more details on the bill click here.

For information on how you can take action to help pass this legislation, check out AA&MDSIF's Grass Roots Action page by clicking here.